Welcome to our dedicated page for Medicure news (Ticker: MCUJF), a resource for investors and traders seeking the latest updates and insights on Medicure stock.
Medicure Inc. (MCUJF) generates regular news flow through financial results, pharmacy acquisitions and updates on its U.S. pharmaceutical and healthcare product operations. The company describes itself as focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, with a present focus on AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets.
News items commonly include quarterly and year-end financial results, where Medicure reports revenue from AGGRASTAT, ZYPITAMAG, and its pharmacy businesses. These releases often discuss performance of Marley Drug, Gateway Medical Pharmacy and West Olympia Pharmacy, as well as research and development spending, including work on the investigational product MC-1 for PNPO deficiency.
Investors following MCUJF can also find announcements about corporate transactions, such as the acquisitions of Gateway Medical Pharmacy and West Olympia Pharmacy through Medicure’s U.S. subsidiary. The company’s news regularly provides details on how these acquisitions relate to its direct-to-consumer pharmacy expansion and support for marketed products like ZYPITAMAG and BRENZAVVY.
Medicure also issues notices about upcoming investor conference calls and webcasts for its quarterly and annual results, including dial-in details and access codes. This news page aggregates those releases so readers can review historical announcements and monitor ongoing developments in Medicure’s pharmaceutical and pharmacy operations.
Medicure Inc. (OTC PINK: MCUJF) reported its financial results for the year and quarter ending December 31, 2022. The company achieved a total net revenue of $23.1 million, up from $21.7 million in 2021. For Q4 2022, revenue was $6.3 million, slightly down from $6.8 million in Q4 2021. Key revenue drivers included AGGRASTAT® sales of $11.7 million and ZYPITAMAG® sales of $3.6 million. Adjusted EBITDA increased to $3.3 million from $2.1 million in the prior year. Net income was reported at $1.4 million or $0.13 per share, compared to a loss of $727,000 in 2021. Despite the positive overall financial performance, Medicure made a marketing hold on sodium nitroprusside due to poor commercial viability.
Medicure Inc. (OTC PINK: MCUJF) will announce its 2022 Year End Financial Results via a conference call on April 10, 2023, at 8:30 AM ET. These results will be filed after market close on April 6, 2023. The call will include a Q&A session for stakeholders to address financial performance and operational questions. Medicure specializes in pharmaceutical development for the U.S. cardiovascular market, marketing drugs like AGGRASTAT® and ZYPITAMAG®. The company operates Marley Drug, a pharmacy enhancing healthcare access nationwide.
Medicure announced the resignation of Board member Gerald McDole, effective January 31, 2023. McDole, who served since 2004, was recognized for his valuable contributions. Additionally, the company granted stock options totaling 1,205,000 shares at $1.25 each to directors, officers, and employees, pending approval from the TSX Venture Exchange. Medicure remains focused on its cardiovascular products in the U.S., including AGGRASTAT® and ZYPITAMAG®. The company aims to improve healthcare access through its pharmacy, Marley Drug, which serves various U.S. locations.
FAQ
What is the current stock price of Medicure (MCUJF)?
What is the market cap of Medicure (MCUJF)?
